Congress mandates free prostate cancer screening for high-risk men
H.R. 1300 — PSA Screening for HIM Act · Filed by Neal Dunn (R-FL) · 36 cosponsors · Introduced Feb 13, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires health insurance plans to cover prostate cancer screening without cost-sharing (copays, deductibles) for men age 40+ who are at high risk—specifically African-American men and men with a family history of prostate cancer. The bill cites data showing African-American men have significantly higher prostate cancer rates and mortality, and that early detection dramatically improves survival. Coverage takes effect January 1, 2026.
Why we flagged it
The bill's operative mechanism is a straightforward insurance coverage mandate targeting a documented health disparity. It amends the Public Health Service Act to add prostate cancer screening to preventive services that must be covered without cost-sharing for high-risk men.
What the text implies
- The bill defines 'high-risk' narrowly (African-American men and those with family history), which may exclude other high-risk populations (e.g., men with certain genetic markers not yet widely screened) and could create a precedent for race-based or ancestry-based insurance coverage categories.
- Removal of cost-sharing may increase screening volume, which could lead to higher rates of PSA-positive results and downstream biopsies—some of which detect clinically insignificant cancers, potentially increasing overtreatment and associated harms.
The full analysis lists 4 implications of this text.
Who stands to gain
health insurance issuers (reduced downstream metastatic cancer treatment costs); urological practices and diagnostic imaging centers (increased screening volume); PSA test manufacturers and laboratory service providers